This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

ImmunoCellular Therapeutics Reports Second Quarter Results

ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) (“ImmunoCellular” or the “Company”), today announced second quarter results for the period ended June 30, 2012.

Highlights of the second quarter and recent weeks include:

Financial Highlights:

  • Ended second quarter with $11.3 million cash, sufficient to fund next 12 months of operations
  • Qualified and listed on the NYSE MKT
  • Added to the Russell 3000®, Global and Microcap Indexes

Clinical and Business Highlights:

  • ICT-107 Phase I clinical data was accepted for publication in prestigious peer-reviewed medical journal: Cancer Immunology, Immunotherapy
  • Expanded enrollment of Phase II clinical trial of ICT-107
  • Presented long-term survival data from Phase I study of ICT-107 at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Brought online second manufacturing site for ICT-107 at a facility run by Progenitor Cell Therapy (PCT)
  • FDA clearance of new IND application for Phase I trial of ICT-121
  • Received important Japanese patent relating to technology for the treatment of brain cancer

The Company incurred $3.1 million in the quarter to support research and development activities and for general operations. Net loss for the quarter of approximately $6.5 million, or $0.16 per basic and diluted share, included an expense for the change in fair value of its warrant liabilities of $3.3 million primarily driven by the increase in the Company’s stock price.

ImmunoCellular Therapeutics, Ltd. Chief Executive Officer Manish Singh commented, “We are pleased by the progress in our Phase II clinical trial of ICT-107. We look forward to continuing to work closely with the investigators and trial sites to complete enrollment and to obtaining patient data.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics ( IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company is currently conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma. To learn more about IMUC, please visit  www.imuc.com

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the safety and efficacy results for ICT-107 seen to date will be confirmed in any current or subsequent trials of that product candidate, or that the data and results will be sufficient to obtain regulatory approval without additional trials.. Additional risks and uncertainties are described in IMUC’s most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. Except as required by law, IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Condensed Balance Sheets    
6/30/2012 12/31/2011
(Unaudited)    
Cash

$

11,339,843

 

$

6,653,168

 

Other current assets 618,086 91,286
Non current assets   106,484       406,303  
Total assets $ 12,064,413     $ 7,150,757  
 
Current liabilities $ 1,021,663 $ 1,761,289
Warrant liability 8,699,007 2,157,408
Shareholders' equity   2,343,743       3,232,060  
$ 12,064,413     $ 7,150,757  
Condensed Statement of Operations (Unaudited)      
 
3 monthsended6/30/2012   3 monthsended6/30/2011   6 monthsended6/30/2012   6 monthsended6/30/2011
Revenue $0 $0 $0 $0
Research and development 2,189,633 858,183 4,188,169 1,775,397
Stock based compensation 103,617 391,858 348,724 633,839
General and administrative 837,322     579,889     1,643,120     1,133,610  
Loss before other expenses (3,130,572 ) (1,829,930 ) (6,180,013 ) (3,542,846 )
Interest income 1,975 1,009 3,009 2,645
Financing expense 0 0 (368,524 ) 0
Change in fair value of warrant liability (3,323,220 )   278,096     (7,795,724 )   (768,895 )
Net loss ($6,451,817 )   ($1,550,825 )   ($14,341,252 )   ($4,309,096 )




Stock quotes in this article: IMUC 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs